Paper Details

  1. Home
  2. Paper Details

Adjuvant treatment of malignant melanoma with DTIC + estracyt or BCG.

Author: EmrichL J, KarakousisC P

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

A study of 82 patients with invasive malignant melanoma compared observation, chemotherapy, and immunotherapy after surgery. While no significant difference in survival was found between the treatment groups, a potential benefit from either treatment cannot be ruled out due to the small sample size. However, the study found a significant difference in disease-free survival based on lymph node status. Patients with negative nodes had an estimated 5-year disease-free rate of 85%, compared to 35% for those with positive nodes (P<0.0001). This highlights the importance of lymph node status in predicting disease recurrence.
Paper Details　
Original Abstract of the Article :
Eighty-two patients with invasive malignant melanoma and no distant metastases were prospectively randomized following their surgical treatment to 1) observation; 2) chemotherapy with Dacarbazine (DTIC) 200 mg/M2 I.V. daily X 5 every 4 weeks and Estracyt 15 mg/kg orally daily for 1 year; and 3) immu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/jso.2930360404

データ提供：米国国立医学図書館（NLM）

Adjuvant Treatment for Malignant Melanoma

Malignant melanoma, a type of skin cancer, can be challenging to treat, especially when it has spread beyond the primary tumor. This research investigates the potential of adjuvant therapies, including chemotherapy with Dacarbazine (DTIC) and Estracyt, and immunotherapy with TICE BCG, to improve outcomes for patients with malignant melanoma.

Adjuvant Therapy: A Complex Landscape

The study found no statistically significant difference in survival rates between the different treatment groups. However, the authors acknowledge the limitations of the study due to the small sample size and highlight the importance of further research to evaluate the effectiveness of these adjuvant therapies.

A Personalized Approach to Melanoma Treatment

This research underscores the need for a personalized approach to treating malignant melanoma, considering factors like the stage of the disease and the patient's individual characteristics. It highlights the importance of ongoing research to identify the most effective treatment options for different patient populations.

Dr.Camel's Conclusion

This study highlights the complexity of melanoma treatment and the need for ongoing research to develop effective therapies. It reminds us that the fight against cancer is a continuous journey, requiring collaboration among researchers, clinicians, and patients to improve outcomes for those affected by this devastating disease.
Date :
  1. Date Completed 1988-01-28
  2. Date Revised 2019-08-20
Further Info :

Pubmed ID

3695527

DOI: Digital Object Identifier

10.1002/jso.2930360404

Related Literature

Article Analysis
・Effective treatment of melanoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.